SCHEMBL1703359

SCHEMBL1703359

CC(=O)Nc1ccsc1C(=O)Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
NAPRT Q6XQN6 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RXFP1 Q9HBX9 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
PRNP P04156 1/20 0.54
PPARG P37231 1/20 0.54
NCOR2 Q9Y618 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.51
MAPK8 P45983 1/20 0.50
MAPK10 P53779 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
PKM P14618 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
MAPT P10636 2/20 0.49
TAAR1 Q96RJ0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704235 0.87 LMNA (0.54) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL13262090 0.84 ALDH1A1 (0.53) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL1703491 0.81 LMNA (0.49) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL1704198 0.80 LMNA (0.51) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL1704250 0.80 PTPN2 (0.68) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL11473233 0.79 L3MBTL1 (0.56) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL1389175 0.79 PKM (0.74) LMNAPPARGNCOR2KMT2AMEN1
SCHEMBL1703806 0.78 L3MBTL1 (0.51) LMNARXFP1NPSR1PRNPPPARG
SCHEMBL1704103 0.78 RAB9A (0.60) LMNANPSR1KMT2AMEN1PKM
SCHEMBL1704322 0.77 MEN1 (0.63) HSD17B10RXFP1NPSR1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ICOS CORPORATION 2010-08-26 US disclosed
EP-2097422-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS Eli Lilly & Co. (US) 2009-09-09 EP disclosed
WO-2008064018-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ELI LILLY & CO. (US) 2008-05-29 WO disclosed
WO-2008064018-A1 THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS ELI LILLY & CO. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216820-A1 THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS PIK3CA, PIK3CD, PIK3CB LMNA 4519/4885NAPRT 1252/4885HSD17B10 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.